MEFV公司
家族性地中海热
外显率
生物
浆膜炎
遗传学
疾病
基因型
人口
医学
表型
内科学
基因突变
基因
突变
环境卫生
作者
Munis Dündar,Umut Fahrioğlu,Saliha Handan Yıldız,Burcu Bakır-Güngör,Şehime Gülsün Temel,Haluk Akın,Sevilhan Artan,Tülin Çora,Feride İffet Şahin,Ahmet Dursun,Özlem Sezer,Hakan Gürkan,Murat Erdoğan,Cumhur Gündüz,Atıl Bişgin,Öztürk Özdemir,Ayfer Ülgenalp,E. Ferda Perçin,Malik Ejder Yıldırım,S. Tekeş
标识
DOI:10.1007/s10142-021-00819-3
摘要
Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder with recurrent fever, abdominal pain, serositis, articular manifestations, erysipelas-like erythema, and renal complications as its main features. Caused by the mutations in the MEditerranean FeVer (MEFV) gene, it mainly affects people of Mediterranean descent with a higher incidence in the Turkish, Jewish, Arabic, and Armenian populations. As our understanding of FMF improves, it becomes clearer that we are facing with a more complex picture of FMF with respect to its pathogenesis, penetrance, variant type (gain-of-function vs. loss-of-function), and inheritance. In this study, MEFV gene analysis results and clinical findings of 27,504 patients from 35 universities and institutions in Turkey and Northern Cyprus are combined in an effort to provide a better insight into the genotype-phenotype correlation and how a specific variant contributes to certain clinical findings in FMF patients. Our results may help better understand this complex disease and how the genotype may sometimes contribute to phenotype. Unlike many studies in the literature, our study investigated a broader symptomatic spectrum and the relationship between the genotype and phenotype data. In this sense, we aimed to guide all clinicians and academicians who work in this field to better establish a comprehensive data set for the patients. One of the biggest messages of our study is that lack of uniformity in some clinical and demographic data of participants may become an obstacle in approaching FMF patients and understanding this complex disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI